COVID-19 Vaccinations


In the United States, there is not yet an authorized or approved vaccine to prevent COVID-19. The federal government, through Operation Warp Speed, has been working since the pandemic started to make one or more COVID-19 vaccines available as soon as possible. (CDC, 2019 )

With the possibility of one or more COVID-19 vaccines becoming available before the end of 2020, here are some benefits and facts from the CDC about COVID-19 vaccines.

BENEFITS of COVID-19 Vaccines

  • COVID-19 vaccination will help keep you from getting COVID-19
  • COVID-19 vaccination will be a safer way to help build protection
  • COVID-19 vaccination will be an important tool to help stop the pandemic

FACTS about COVID-19 Vaccines

  • COVID-19 vaccines will not give you COVID-19
  • COVID-19 vaccines will not cause you to test positive on COVID-19 viral tests
  • People who have gotten sick with COVID-19 may still benefit from getting vaccinated
  • Getting vaccinated can help prevent getting sick with COVID-19
  • Receiving an mRNA vaccine will not alter your DNA

8 Thing to Know About Vaccine Planning (CDC)

  • The safety of COVID-19 vaccines is a top priority.
  • Many vaccines are being developed and tested, but some might be ready before others—CDC is planning for many possibilities.
  • At least at first, COVID-19 vaccines might be used under an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
  • There will be a limited supply of COVID-19 vaccines in December 2020, but supply will continually increase in the weeks and months that follow.
  • Because of limited supply, some groups will be recommended to get a COVID-19 vaccine first.
  • At first, COVID-19 vaccines may not be recommended for children.
  • Cost will not be an obstacle to getting vaccinated against COVID-19.
  • COVID-19 vaccine planning is being updated as new information becomes available. (Check CDC website for new information)
This entry was posted in COVID News and tagged , . Bookmark the permalink.

Comments are closed.